Related Experiment Video
Updated: Aug 7, 2025
04:01
Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma
Published on: September 15, 2023
847
Radiotherapy for primary thyroid adenoid cystic carcinoma
Xiaoyu Duan1,2, Tingting Hu2, Hongyi Cai2
1The First Clinical Medical College, Gansu University of Chinese Medicine, Number 35 Ding Xing East Road, Lanzhou, 730000 China.
Open Life Sciences
|March 13, 2023
Summary
Primary thyroid adenoid cystic carcinoma (PTACC) is a rare cancer. Postoperative radiotherapy may improve patient outcomes for this challenging diagnosis.
Area of Science:
- Oncology
- Endocrinology
Background:
- Primary thyroid adenoid cystic carcinoma (PTACC) is an exceedingly rare mucin-secreting adenocarcinoma.
- Diagnosis and treatment protocols for PTACC remain challenging due to its rarity.
Observation:
- A 53-year-old female patient with PTACC was treated with surgery followed by intensity-modulated radiotherapy.
- The patient experienced an uneventful recovery and showed no signs of invasion or distant metastasis at a 7-month follow-up.
Findings:
- The case highlights key diagnostic features of PTACC.
- Postoperative adjuvant radiotherapy was associated with a favorable prognosis in this patient.
Implications:
- Adjuvant radiotherapy may significantly improve prognosis for PTACC patients.
- This case and literature review offer valuable treatment insights for clinicians managing PTACC.
